AIIMS: 8-10 months protection possible with C-19 vaccine

The C-19 vaccine should be able to give good protection from the infection for eight to ten months and maybe, even more - AIIMS

96
AIIMS Hospital

Last Updated on March 22, 2021 by The Health Master

The C-19 vaccine should be able to give good protection from the infection for eight to ten months, AIIMS director Randeep Guleria said. He also said that no major side-effect of the vaccine has been recorded.

The C-19 vaccine should be able to give good protection from the infection for eight to ten months and maybe, even more,” Guleria said at an event organised by the IPS (Central) Association.

He said the biggest reason for the surge in cases is that people feel the pandemic is over and they are not following C-19-appropriate behaviour.

“There are multiple reasons for the surge, but the main reason is that there is change in people’s attitude and they feel coronavirus is over. People should still restrict non-essential travel for some more time,” the official asserted.

Injection vaccine Medicine
Picture: Pixabay

NITI Aayog member (Health) V K Paul said the chain of transmission has to be stopped and for that vaccine is one tool but another is containment and surveillance strategy. “Not following C-19 behaviour and laxity is major reason for the surge,” he said.

Responding to a question on vaccinating more people, Paul said the issue is vaccines are limited and that is why, prioritisation has been done.


Also read:

How Pharmaceutical Industry can avoid Cyberattacks

Govt brings two vaccines for animal use under NLEM

NPPA fixes retail price of 41 formulations

FAQs – on Alcohol (in Pharma Industry)

NPPA & ICMR together will check usage of Cocktail drugs


“If we had unlimited supply, we would open the vaccination for everyone. That is the reason, not everyone, is getting vaccinated. Most countries in the world are not able to go beyond priority group because of this reason,” he said.

The NITI Aayog member also said that the highest mortality was seen among people with co-morbidities and older age groups.

“These people must not delay taking the vaccine. So the message is that they need it more than others. That is the reason they have been prioritised for getting the C-19 vaccine,” he said.

Talking about the effectiveness of the available C-19 vaccines, Covaxin and Covishield, Guleria said, “If we look at the two vaccines, they produce equal antibodies and are very robust.

We should take the vaccine available to us because both are equally effective in terms of efficacy and long-term protection.”

Over four crore people in the country have been vaccinated against the disease till now. Under the current phase of the inoculation drive, people above 60 years of age and those in the 45-59 years age bracket with co-morbidities, are being vaccinated.

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner